Oramed Pharmaceuticals Inc.
ORMPNASDAQHealthcare● Active
$3.71
+$0.07(+1.92%)
Market Cap$151835761
P/E Ratio—
52W High$5.01
52W Low$1.98
Oramed Pharmaceuticals Inc. (ORMP) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ORMP · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-08 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $64.02M | ($19.06M) | $5.53M | ($36.56M) | ($22.24M) |
| Depreciation & Amort. | $0.12M | $0.19M | $0.20M | $0.06M | $0.08M |
| Stock-Based Comp. | $5.99M | $0.00M | $0.00M | $0.00M | $0.00M |
| Change in Working Capital | ($1.91M) | $3.20M | ($2.70M) | ($0.94M) | ($1.31M) |
| Net Cash from Operations | ($9.14M) | ($8.41M) | ($10.29M) | ($28.70M) | ($21.18M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.93M) | ($0.02M) | ($0.25M) | ($0.50M) | ($0.37M) |
| Purchases of Investments | ($88.51M) | ($55.76M) | ($190.92M) | ($154.41M) | ($53.82M) |
| Sales of Investments | $96.88M | $161.65M | $118.14M | $185.09M | $30.43M |
| Net Cash from Investing | $5.44M | $105.82M | ($73.04M) | $30.21M | ($22.26M) |
| Financing Activities | |||||
| Common Stock Repurchased | ($4.74M) | ($2.48M) | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($49.55M) | $49.55M | — | — |
| Net Cash from Financing | ($4.74M) | ($52.04M) | $51.98M | $11.56M | $101.39M |
| Free Cash Flow | |||||
| Free Cash Flow | ($11.08M) | ($8.43M) | ($10.55M) | ($29.20M) | ($21.56M) |
| FCF Margin %(computed) | -553.90% | — | -787.24% | — | -797.48% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Oramed Pharmaceuticals Inc. data
About Oramed Pharmaceuticals Inc. (ORMP) Cash Flow Statement
Oramed Pharmaceuticals Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -553.90%. Capital expenditure was ($0.00B).
Frequently asked questions
ORMP · 4 questionsOramed Pharmaceuticals Inc. generated free cash flow of ($0.01B) for 2025, down 31.4% year-over-year.
ORMP free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10